Skip to main content

Table 1 Patient and tumor characteristics

From: Feasibility of radioguided occult lesion localization of clip-marked lymph nodes for tailored axillary treatment in breast cancer patients treated with neoadjuvant systemic therapy

  n (%)
No. of procedures 38
Median age (years) 51 (range 31–83)
cT-stage prior to NST
 Tis 1 (2.6)
 1 4 (10.5)
 2 23 (60.5)
 3 6 (15.8)
 4 4 (10.5)
cN-stage prior to NST
 1 23 (60.5)
 2 9 (23.7)
 3 6 (15.8)
Axillary lymph node stage on pretreatment PET/CT
 cN<4 (< 4 18F-FDG-avid nodes) 26 (68.4)
  1 10
  2 14
  3 2
 cN4+ (≥ 4 18F-FDG-avid nodes) 12 (31.6)
Tumor histology
 Ductal carcinoma in situ 1 (2.6)
 Ductal carcinoma 33 (86.8)
 Lobular carcinoma 3 (7.9)
 Other 1 (2.6)
Receptor status
 HR-positive/HER2-negative 28 (73.7)
 Triple negative 6 (15.8)
 HER2-positive 4 (10.5)
NST regimen
 ddAC 7 (18.4)
 ddAC + paclitaxel 21 (55.3)
 ddAC + CP 3 (7.9)
 CP 2 (5.3)
 PTC-P 3 (7.9)
 Endocrine 2 (5.3)
  1. Tis ductal carcinoma in situ, 18F-FDG [18F]fluorodeoxyglucose, PET/CT positron emission tomography combined with computed tomography, HR hormone receptor, HER2 human epidermal growth factor receptor 2, NST neoadjuvant systemic treatment, ddAC doxorubicine and cyclophosphamide (dose dense), CP carboplatin and paclitaxel, PTC-P paclitaxel, trastuzumab, carboplatin, and pertuzumab